Synergistic latency reversal by the IAP antagonist AZD5582 and BET inhibitor JQ1, combined with Nef ablation, facilitates immune-mediated elimination of latently HIV-1-infected T-cells

This study demonstrates that combining the IAP antagonist AZD5582 and BET inhibitor JQ1 to reverse HIV-1 latency, alongside Nef ablation to prevent immune evasion, effectively facilitates the immune-mediated elimination of latently infected T-cells, offering a promising strategy for an HIV cure.

The Gist

The Big Picture: The "Shock and Kill" Game

Imagine HIV is a master spy hiding inside your body's security guards (your immune cells). The spy has a "sleep mode" (latency) where it turns off its lights and stops making noise so the security system can't find it.

The current strategy to cure HIV is called "Shock and Kill."

• The Shock: You wake the spy up using drugs (Latency Reversal Agents) so it starts making noise and flashing its lights (viral proteins).
• The Kill: Once the spy is visible, your immune system's "hitmen" (antibodies and killer cells) can spot it and destroy it.

The Problem: In the past, this strategy has mostly failed. The spies wake up, but they are still too good at hiding, or they are too tough to kill. This paper asks: Why does the "Kill" part fail, and how can we fix it?

---

The Experiment: Testing Different "Wake-Up" Calls

The researchers tested different combinations of drugs to see which one wakes the virus up best and makes it easiest to kill. They used a special model: a "training ground" of immune cells where each cell had exactly one sleeping HIV spy.

They compared two main teams of drugs:

1. Team A: Bryostatin-1 + JQ1
2. Team B: AZD5582 + JQ1

Team A (Bryostatin-1 + JQ1): The "Overzealous Alarm"

This combination was great at waking the virus up. However, it had two major flaws:

• The "Foggy Window" Effect: When the virus woke up, it tried to show its "ID card" (a protein called Env) on the cell surface. But Bryostatin-1 accidentally triggered a cellular alarm system (a protein called GBP5) that acted like a fog machine. It covered the ID card, making it hard for the immune system to see the virus clearly.
• The "Bulletproof Vest" Effect: Bryostatin-1 also woke up the immune cell itself, making it very active. Unfortunately, active immune cells are tough. They put on a "bulletproof vest" (resistance to apoptosis) that made them very hard to kill, even when the virus was visible.

Result: The virus woke up, but it was wearing a foggy mask and a bulletproof vest. The immune system couldn't kill it effectively.

Team B (AZD5582 + JQ1): The "Clean Break"

This combination was a different story.

• Clear Visibility: It woke the virus up and let the ID card (Env) shine clearly on the surface. No foggy masks.
• No Bulletproof Vest: It did not trigger the "bulletproof vest" response. The cells remained vulnerable and ready to be eliminated.

Result: The virus was wide awake, fully visible, and defenseless. This team was much better at the "Kill" part of the strategy.

---

The Secret Villain: The "Nef" Protein

Even with Team B, there was still a problem. The virus has a sneaky little accessory protein called Nef. Think of Nef as the spy's personal bodyguard.

• What Nef does: Even when the virus is awake, Nef sneaks around and:
  1. Steals the "ID card" (Env) from the surface.
  2. Puts a "Do Not Disturb" sign on the cell to stop the immune system from attacking.
  3. Blocks the cell's self-destruct button (apoptosis).

The Solution: The researchers used a molecular "eraser" (CRISPR/Cas9) to delete the gene for Nef.

• Without Nef: When they used Team B (AZD5582 + JQ1) on cells without the Nef bodyguard, the result was spectacular. The virus was fully visible, the cells were vulnerable, and the immune system wiped out almost all the infected cells.

---

The Takeaway: A New Blueprint for a Cure

This paper tells us that simply "waking up" the virus isn't enough. We have to be careful how we wake it up.

1. Don't use the wrong drugs: Some drugs (like Bryostatin-1) might wake the virus up but accidentally make the cell harder to kill or hide the virus again.
2. Use the right combo: The combination of AZD5582 and JQ1 is a winner because it wakes the virus up without making the cell tough.
3. Disarm the bodyguard: The most important step is to stop the virus's bodyguard, Nef. If you wake the virus up with the right drugs and remove Nef, the immune system can finally do its job and clear the infection.

In short: To cure HIV, we need a strategy that wakes the spy up, removes its foggy mask, takes away its bulletproof vest, and disarms its bodyguard, all at the same time. This paper shows us exactly how to do that.

Technical Summary

1. The Problem

The "shock-and-kill" strategy for an HIV cure aims to reactivate latent HIV-1 proviruses ("shock") to make infected cells visible to the immune system, followed by the elimination of these cells ("kill"). However, clinical trials have largely failed to significantly reduce the viral reservoir. The authors hypothesize that current approaches suffer from two main shortcomings:

1. Insufficient Immunological Visibility: Reactivated cells may not present sufficient viral antigens (specifically the Env glycoprotein) on their surface for antibody recognition.
2. Resistance to Killing: Reactivated cells may acquire phenotypic changes (e.g., resistance to apoptosis) or express viral proteins (like Nef) that actively protect them from cytotoxic immune mechanisms, such as Antibody-Dependent Cellular Cytotoxicity (ADCC) and T-cell mediated killing.

There is a lack of detailed understanding regarding how specific Latency Reversal Agents (LRAs) and their combinations affect cellular states, antigen presentation, and susceptibility to killing.

2. Methodology

The study utilized a novel, rigorous experimental model to dissect the "shock" and "kill" components separately and in combination:

• Novel Cell Model (JLEG): The authors generated Jurkat E6.1 T-cell subclones (JLEG.1, JLEG.60, JLEG.74), each harboring a single, full-length, replication-competent HIV-1 NL4.3 provirus. Crucially, this provirus contains a GFPOPT reporter fused into the Env V5 loop. This allows for:
  • Single-cell resolution tracking of reactivation.
  • Distinction between reactivating (EnvGFP+) and non-reactivating (EnvGFP-) cells within the same sample.
  • Direct assessment of cell-surface Env presentation.
• LRA Combinations Tested:
  • Bryostatin-1 (Bryo) + JQ1: A Protein Kinase C (PKC) agonist combined with a Bromodomain and Extraterminal (BET) inhibitor.
  • AZD5582 (AZD) + JQ1: An Inhibitor of Apoptosis Protein (IAP) antagonist combined with a BET inhibitor.
  • Controls: Panobinostat (HDAC inhibitor), Bryo alone, JQ1 alone, AZD alone.
• Assays Performed:
  • Flow Cytometry: Quantified p24CA (viral protein), total EnvGFP, and cell-surface EnvGFP. Measured T-cell activation markers (CD25, CD69, PD-1, PD-L1) and restriction factors (GBP5).
  • RNA Sequencing (RNA-seq): Analyzed transcriptomic changes, pathway enrichment, and gene expression profiles in infected vs. uninfected cells.
  • Apoptosis Assays: Measured susceptibility to intrinsic (etoposide/menadione) and extrinsic (anti-CD95) apoptosis.
  • ADCC Assays: Co-cultured reactivated target cells with PBMCs from HIV-negative donors and pooled anti-HIV sera to measure cytotoxic killing efficiency.
  • CRISPR/Cas9 Knockouts: Generated isogenic cell lines with GBP5 knockout and Nef knockout to determine the causal role of these factors in Env restriction and apoptosis resistance.

3. Key Contributions

• Development of the JLEG Model: A superior model for HIV latency studies that allows simultaneous quantification of reactivation, antigen presentation, and cell death at the single-cell level, overcoming limitations of reporter-only systems (like J-Lat) that lack full viral gene expression.
• Identification of LRA-Specific "Kill" Barriers: Demonstrated that while some LRAs effectively "shock" (reactivate) the virus, they simultaneously induce cellular states that prevent "killing."
• Mechanistic Insight into GBP5: Identified that Bryostatin-1 induces the restriction factor GBP5, which actively restricts the trafficking of HIV-1 Env to the cell surface, reducing immunological visibility.
• Role of Nef in Apoptosis Resistance: Provided the first evidence that Nef protects reactivating T-cells from both intrinsic and extrinsic apoptosis during latency reversal, acting as a major barrier to the "kill" phase.
• Proposed Optimized Strategy: Validated that the combination of AZD5582 + JQ1 (synergistic reactivation without T-cell activation/GBP5 induction) combined with Nef ablation yields the highest immune-mediated elimination.

4. Key Results

A. Bryostatin-1 Induces Restrictive Phenotypes

• Latency Reversal: Bryo + JQ1 synergistically reactivated HIV-1.
• Env Restriction: Despite high total Env production, Bryo treatment led to a decrease in cell-surface Env over time (24h to 48h).
• Mechanism: RNA-seq and flow cytometry revealed that Bryo induces GBP5 (a guanylate-binding protein). GBP5 interferes with Env biosynthesis and trafficking. Knockout of GBP5 restored cell-surface Env levels, confirming GBP5 as the cause of restricted visibility.
• Apoptosis Resistance: Bryo + JQ1 treatment induced T-cell activation (upregulation of CD69, CD25, PD-L1) and phosphorylation of Bad (S112), rendering cells resistant to intrinsic apoptosis. Consequently, ADCC killing was poor despite high viral reactivation.

B. AZD5582 + JQ1 is Superior for "Shock-and-Kill"

• Reactivation: AZD + JQ1 potently reactivated HIV-1 and induced high levels of cell-surface Env.
• No Restriction: Unlike Bryo, this combination did not induce GBP5, T-cell activation markers, or apoptotic resistance.
• Outcome: Reactivated cells remained susceptible to apoptosis and were efficiently killed via ADCC.

C. The Critical Role of Nef

• Apoptosis Evasion: Even with potent reactivation, wild-type HIV-1 reactivating cells were resistant to apoptosis compared to non-reactivating cells.
• Nef Knockout Effects:
  • Increased Apoptosis: Removing Nef significantly increased susceptibility to both intrinsic and extrinsic apoptosis.
  • Enhanced ADCC: Nef knockout led to higher cell-surface Env levels (partially due to Nef's role in downregulating CD4, which shifts Env to an "open" conformation) and increased ADCC-mediated killing.
  • Synergy: The combination of AZD5582 + JQ1 + Nef knockout resulted in the highest total elimination of infected cells across all tested clones.

D. ADCC Co-factors

• The study ruled out the modulation of ADCC co-factors (CD48, SLAMF6, PVR) as the primary cause of poor killing in Bryo-treated cells, pointing instead to GBP5-mediated Env restriction and apoptosis resistance.

5. Significance

• Paradigm Shift in LRA Selection: The study argues that efficacy in "shock-and-kill" cannot be judged solely by the ability to reactivate viral transcription. An ideal LRA must also avoid inducing cellular states (like activation or GBP5 expression) that shield the cell from immune clearance.
• Nef as a Therapeutic Target: The findings establish Nef as a critical antagonist of the "kill" phase. Future cure strategies must incorporate Nef inhibition or ablation (e.g., via CRISPR or small molecules) alongside latency reversal.
• Clinical Implications: The combination of AZD5582 (IAP antagonist) and JQ1 (BET inhibitor), potentially paired with Nef-targeting agents, is proposed as a superior blueprint for clinical trials. This approach maximizes viral reactivation, ensures high antigen visibility, and removes viral barriers to apoptosis, thereby facilitating effective immune-mediated clearance of the reservoir.
• Translational Potential: The safety profile of AZD5582 and JQ1 in other contexts (e.g., cancer) and their synergistic efficacy in this model suggest a viable path forward for HIV cure research.